SPRAVATO®
(esketamine)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SPRAVATO® (esketamine)
Medical Information
Return or Disposal of SPRAVATO
Last Updated: 09/19/2024
summary
- Because of the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse and misuse, SPRAVATO (esketamine) nasal spray is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).1
- For additional information or questions about the REMS, call 1-855-382-6022 or visit www.SPRAVATOrems.com.
- SPRAVATO nasal spray devices must be handled with adequate security, accountability, and proper disposal as medical waste, per facility procedure for used Schedule III drug product and per applicable federal, state, and local regulations.1 According to recommendations from the Centers for Disease Control and Prevention (CDC) for environmental cleaning and disinfection for SARS-CoV-2, management of medical waste should be performed in accordance with routine procedures.2
Managing Used, Partially Used and Unused Devices
Abbreviations: CIII, Schedule III controlled substance; J&J, Johnson & Johnson.
a
b
Abbreviations: DEA, Drug Enforcement Administration; NDC, National Drug Code; UPS, United Parcel Service.
Literature Search
A literature search of MEDLINE®
References
| 1 | SPRAVATO (esketamine) nasal spray [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf. |
| 2 |